Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences logo
$103.76 -1.48 (-1.40%)
Closing price 11/19/2026 03:59 PM Eastern
Extended Trading
$103.90 +0.15 (+0.14%)
As of 08:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Edwards Lifesciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
3
Buy
23

Based on 26 Wall Street analysts who have issued ratings for Edwards Lifesciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 3 have given a hold rating, and 23 have given a buy rating for EW.

Consensus Price Target

$109.88
5.90% Upside
According to the 26 analysts' twelve-month price targets for Edwards Lifesciences, the average price target is $109.88. The highest price target for EW is $121.00, while the lowest price target for EW is $85.00. The average price target represents a forecasted upside of 5.90% from the current price of $103.76.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for EW and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Edwards Lifesciences and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EW Analyst Ratings Over Time

TypeCurrent Forecast
11/20/25 to 11/20/26
1 Month Ago
10/21/25 to 10/21/26
3 Months Ago
8/22/25 to 8/22/26
1 Year Ago
11/20/24 to 11/20/25
Strong Buy
0 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
3 Strong Buy rating(s)
Buy
23 Buy rating(s)
18 Buy rating(s)
19 Buy rating(s)
14 Buy rating(s)
Hold
3 Hold rating(s)
7 Hold rating(s)
8 Hold rating(s)
10 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$109.88$100.27$100.54$91.20
Forecasted Upside5.90% Upside13.49% Upside11.85% Upside8.43% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

EW Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

EW Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Edwards Lifesciences Stock vs. The Competition

TypeEdwards LifesciencesHealthcare CompaniesBroader Market
Consensus Rating Score
2.88
2.32
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside5.90% Upside117.31% Upside19.14% Upside
News Sentiment Rating
Positive News

See Recent EW News
Neutral News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
11/16/2026
Lawrence Biegelsen
Lawrence Biegelsen
1 of 5 stars
Boost TargetOverweight$113.00 ➝ $121.00+12.91%
11/11/2026
TD Cowen logo
TD Cowen
3 of 5 stars
Joshua Jennings
3 of 5 stars
Boost TargetBuy$117.00 ➝ $121.00+15.66%
11/9/2026
Weiss Ratings logo
Weiss Ratings
2 of 5 stars
 UpgradeHold (C) ➝ Hold (C+)
11/5/2026Set Target$120.00+20.74%
11/5/2026Boost TargetBuy$110.00 ➝ $118.00+17.18%
11/5/2026Boost TargetOverweight$105.00 ➝ $120.00+19.16%
11/5/2026Boost TargetBuy$110.00 ➝ $117.00+16.18%
11/5/2026Boost TargetOutperform$101.00 ➝ $112.00+11.59%
11/5/2026Boost TargetOutperform$110.00 ➝ $115.00+15.46%
11/5/2026Boost TargetOverweight$110.00 ➝ $120.00+20.51%
11/5/2026Boost TargetMarket Perform$99.00 ➝ $106.00+6.69%
11/5/2026Reiterated RatingOverweight$101.00 ➝ $115.00+14.46%
11/5/2026Boost TargetBuy$110.00 ➝ $115.00+15.71%
11/5/2026 UpgradeNeutral ➝ Outperform$116.00+16.72%
11/4/2026Set TargetHold ➝ Buy$95.00 ➝ $113.00+18.55%
10/27/2026 Set Target$104.00+14.86%
10/23/2026Reiterated RatingOutperform
8/21/2026 Boost TargetBuy$105.00 ➝ $115.00+30.22%
7/27/2026 Boost TargetBuy$99.00 ➝ $102.00+15.50%
7/24/2026 Boost TargetBuy$102.00 ➝ $105.00+18.89%
7/24/2026 Boost TargetOutperform$100.00 ➝ $103.00+16.63%
7/14/2026 Boost TargetBuy$98.00 ➝ $102.00+15.50%
4/24/2026Set TargetHold$87.00 ➝ $85.00+2.10%
4/1/2026 UpgradePeer Perform ➝ Outperform$92.00+14.91%
2/24/2026 Lower TargetBuy$99.00 ➝ $98.00+11.03%
1/20/2026Set TargetBuy$105.00 ➝ $110.00+30.35%
10/31/2025 Set Target$92.00+11.54%
10/8/2025DowngradeOutperform ➝ Market Perform
7/25/2025 UpgradeStrong-Buy
7/15/2025Boost TargetEqual Weight$75.00 ➝ $81.00+3.39%
6/2/2025UpgradeHold
12/16/2024 UpgradeNeutral ➝ Buy$82.00 ➝ $90.00+20.97%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 08:19 AM ET.


Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, November 17, 2026. Please send any questions or comments about these Edwards Lifesciences pros and cons to contact@marketbeat.com.

Edwards Lifesciences
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.:

  • The stock is trading at $106.95, which is near its 52-week high of $108.00, indicating strong recent momentum and investor confidence in the company's performance.
  • Edwards Lifesciences Co. recently reported Q3 2026 earnings with an EPS of $0.80, beating the consensus estimate of $0.74, and revenue of $1.72 billion, which exceeded the $1.68 billion estimate, demonstrating strong fundamental execution.
  • The company has a "Moderate Buy" consensus rating from 26 analysts, with a recent price target increase by Wells Fargo to $121.00, suggesting significant potential upside from the current price.
  • Institutional investors are increasing their stakes, with Aberdeen Group plc boosting its holdings by 49.9% in the third quarter and Jefferies Financial Group Inc. increasing its position by 649.1%, signaling strong institutional support.
  • The company maintains a strong balance sheet with a quick ratio of 3.86 and a current ratio of 4.60, indicating ample liquidity to support operations and growth initiatives.

Edwards Lifesciences
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons:

  • The stock has a high price-to-earnings ratio of 60.42, which may indicate that the stock is overvalued relative to its current earnings, posing a risk if growth slows.
  • Insider selling has been significant, with VP Donald E. Bobo Jr. selling 48,900 shares in November 2026 and other executives like Daniel J. Lippis and Scott B. Ullem also selling shares, which could signal a lack of confidence from company insiders.
  • Short interest has increased slightly, with 9,382,239 shares shorted as of October 30, 2026, representing 1.64% of the float, indicating some bearish sentiment among traders.
  • The company's dividend yield is 0.00%, meaning it does not provide income to investors, which may be a drawback for those seeking regular cash flow from their investments.
  • The stock's beta of 0.85 suggests it is less volatile than the market, but this also means it may underperform in strong bull markets, limiting upside potential for aggressive investors.

EW Forecast - Frequently Asked Questions

According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Edwards Lifesciences is $109.88, with a high forecast of $121.00 and a low forecast of $85.00.

26 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 3 hold ratings and 23 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EW shares.

According to analysts, Edwards Lifesciences's stock has a predicted upside of 5.90% based on their 12-month stock forecasts.

Over the previous 90 days, Edwards Lifesciences's stock had 4 upgrades by analysts.

Analysts like Edwards Lifesciences more than other "healthcare" companies. The consensus rating for Edwards Lifesciences is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how EW compares to other companies.


MarketBeat monitors more than a dozen sources for Edwards Lifesciences analyst ratings, with the most recent rating issued on 11/16/2026.
From Our Partners